Arena Pharmaceuticals, Inc. (ARNA) Misses Q1 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. LEVI
3. SBUX
4. NVDA
5. GOOGL
6. AAPL
7. SPY
8. APLD
9. ORCL
10. USO

Go back to Arena Pharmaceuticals, Inc. (ARNA) Misses Q1 EPS by 2c

Arena Pharma (ARNA) Posts Modest BELVIQ Sales, BMO Capital Notes

May 13, 2014 8:02 AM EDT

BMO Capital analyst Jim Birchenough, M.D. reiterated a Market Perform rating on Arena Pharma (NASDAQ: ARNA) following a Q1 net loss of $0.12 versus the consensus of a $0.10 loss, and an ending cash balance of $256.5 million.

The analyst also highlights revenues were $6.8 million, including $2.9 million in net product sales of weight loss drug BELVIQ, of which $2.7 million... More